Sensitivity of common marmosets to detect drug-induced QT interval prolongation: Moxifloxacin case study

Journal of Pharmacological and Toxicological Methods

Volumn 61, Issue 3, 2010, Pages 271-276

  Komatsu, Ryuichi ^a   Honda, Masaki ^a   Holzgrefe, Henry H ^b   Kubo, Jun ichi ^a   Yamada, Yuichiro ^a   Isobe, Takehito ^a   Kimura, Kazuya ^a   Itoh, Toshio ^c   Tamaoki, Norikazu ^c   Tabo, Mitsuyasu ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

Author keywords

Common marmoset; Moxifloxacin; Probabilistic QT analysis; QT interval prolongation; Safety pharmacology; Telemetry

Indexed keywords

MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; ELECTROCARDIOGRAM; FEMALE; MALE; MARMOSET; MAXIMUM PLASMA CONCENTRATION; MONITORING; NONHUMAN; PHARMACODYNAMICS; QT INTERVAL; QT PROLONGATION; SENSITIVITY ANALYSIS; TELEMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; AZA COMPOUNDS; CALLITHRIX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; LONG QT SYNDROME; MALE; QUINOLINES; SPECIES SPECIFICITY; TIME FACTORS;

ANIMALIA; CALLITHRIX JACCHUS;

EID: 77952288795     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.01.006     Document Type: Article

References (21)

1. Balfour J.A.B., Wiseman L.R. Moxifloxacin. Drugs 1999, 57:363-373.
2. Chaves A.A., Keller W.J., O'Sullivan S., Williams M.A., Fitzgerald L.E., McPherson H.E., et al. Cardiovascular monkey telemetry: Sensitivity to detect QT interval prolongation. Journal of Pharmacological and Toxicological Methods 2006, 54:150-158.
3. Chaves A.A., Zingaro G.J., Yordy M.A., Bustard K.A., O'Sullivan S., Galijatovic-Idrizbegovic A., et al. A highly sensitive canine telemetry model for detection of QT interval prolongation: Studies with moxifloxacin, haloperidol and MK-499. Journal of Pharmacological and Toxicological Methods 2007, 56:103-114.
4. Chen X., Cass J.D., Bradley J.A., Dahm C.M., Sun Z., Kadyszewski E., et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. British Journal of Pharmacology 2005, 146:792-799.
5. Demolis J.-L., Kubitza D., Tenneze L., Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400mg and 800mg) on ventricular repolarization in healthy subjects. Clinical Pharmacology and Therapeutics 2000, 68:658-666.
6. De Ponti F., Poluzzi E., Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus. European Journal of Clinical Pharmacology 2001, 57:185-209.
7. Dixon R., Job S., Oliver R., Tompson D., Wright J.G., Maltby K., et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology 2008, 66:396-404.
8. Holzgrefe H.H., Cavero I., Buchanan L.V., Gill M.W., Durham S.K. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of moxifloxacin. Journal of Pharmacological and Toxicological Methods 2007, 55:244-254.
9. Holzgrefe H.H., Cavero I., Gleason C.R. Analysis of the nonclinical telemetered ECG: Impact of logging rate and RR bin width in the dog and cynomolgus monkey. Journal of Pharmacological and Toxicological Methods 2007, 56:34-42.
10. Holzgrefe H.H., Cavero I., Gleason C.R., Warner W.A., Buchanan L.V., Gill M.W., et al. Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 2007, 55:159-175.
11. Hulhoven R., Rosillon D., Letiexhe M., Meeus M.-A., Daoust A., Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: Results from a thorough QT study. European Journal of Clinical Pharmacology 2007, 63:1011-1017.
12. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs (E14). (2005). ICH; http://www.ich.org/.
13. ICH Harmonised Tripartite Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B). (2005). ICH; http://www.ich.org/.
14. Komatsu, R., Honda, M., Yamada, Y., Isobe, T., Itoh, T., and Tamaoki, N., et al. (2009, September). Application of a probabilistic analytical method to detect drug-induced QT interval prolongation in telemetered common marmosets: Effects of moxifloxacin. Abstract presented at the Safety Pharmacology Society Meeting, Strasburg, France, September 2009.
15. Malhotra B.K., Glue P., Sweeney K., Anziano R., Mancuso J., Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clinical Pharmacology and Therapeutics 2007, 81:377-385.
16. Miyazaki H., Tagawa M. Rate-correction technique for QT interval in long-term telemetry ECG recording in beagle dogs. Experimental Animals 2002, 51:465-475.
17. Shah R.R. Drugs, QT interval prolongation and ICH E14: The need to get it right. Drug Safety 2005, 28:115-125.
18. Spence S., Soper K., Hoe C.M., Coleman J. The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance. Toxicological Sciences 1998, 45:247-258.
19. Stass H., Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. Journal of Chromatography B: Biomedical Sciences and Applications 1997, 702:163-174.
20. Tabo M., Hara T., Sone S., Shishido N., Kuramoto S., Nakano K., et al. Prediction of drug-induced QT interval prolongation in telemetered common marmosets. Journal of Toxicological Sciences 2008, 33:315-325.
21. Zhang L., Chappell J., Gonzales C.R., Small D., Knadler M.P., Callaghan J.T., et al. QT effects of duloxetine at supratherapeutic doses: A placebo and positive controlled study. Journal of Cardiovascular Pharmacology 2007, 49:146-153.